The role of acute care surgery in the treatment of severe, complicated Clostridium difficile-associated disease

被引:26
作者
Carchman, Evie H. [1 ]
Peitzman, Andrew B. [1 ]
Simmons, Richard L. [1 ]
Zuckerbraun, Brian S. [1 ]
机构
[1] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
关键词
HUMAN-ANTIBODY RESPONSE; HOSPITALIZED-PATIENTS; EMERGENCY COLECTOMY; COLITIS-PREDICTORS; RISK-FACTORS; TOXIN-A; INFECTION; DIARRHEA; VANCOMYCIN; METRONIDAZOLE;
D O I
10.1097/TA.0b013e318265d19f
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Clostridium difficile associated disease (CDAD) is the result of colonic bacterial overgrowth with this gram positive anaerobic organism and the production of toxins that typically induce diarrhea. Most patients with CDAD respond to treatment with oral metronidazole or vancomycin, but a subset of patients will develop a severe systemic illness, multiple organ failure, and death. There are no reliable combinations of clinical or laboratory findings that will distinguish patients who will respond to medical therapy and those who will progress to a more complicated state. Early surgical consultation should be considered in patients with ileus, severe abdominal pain, significant tenderness, immunosuppression, advanced age, high white blood cell or band counts, acute renal failure, mental status changes, or cardiopulmonary compromise. The standard operation for fulminant colitis is subtotal colectomy but the high mortality of the operation, and the long-term morbidity even in survivors combine to act as deterrents to early surgical consultation and operation. Novel operative approaches that preserve the colon and minimize operative morbidity may prove to remove the barriers to earlier surgical treatment for fulminant CDAD and improve outcomes.
引用
收藏
页码:789 / 800
页数:12
相关论文
共 77 条
[1]  
Ali SO, 2008, AM SURGEON, V74, P20
[2]  
[Anonymous], HCUPnet
[3]   SERUM ANTIBODY-RESPONSE TO CLOSTRIDIUM DIFFICILE TOXINS IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DIARRHEA [J].
ARONSSON, B ;
GRANSTROM, M ;
MOLLBY, R ;
NORD, CE .
INFECTION, 1985, 13 (03) :97-101
[4]   Antibiotic-associated diarrhea [J].
Bartlett, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (05) :334-339
[5]   The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection [J].
Bartlett, John G. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (10) :1489-1492
[6]   Clinical recognition and diagnosis of Clostridium difficile infection [J].
Bartlett, John G. ;
Gerding, Dale N. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 :S12-S18
[7]   New antimicrobial agents for patients with Clostridium difficile infections [J].
Bartlett J.G. .
Current Infectious Disease Reports, 2009, 11 (1) :21-28
[8]   Measuring the severity of Clostridium difficile infection: implications for management and drug development [J].
Belmares, Jaime ;
Gerding, Dale N. ;
Tillotson, Glenn ;
Johnson, Stuart .
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2008, 6 (06) :897-908
[9]  
Bergamin B, 2000, SCHWEIZ MED WSCHR, V130, P1681
[10]   Endoscopic Fecal Microbiota Transplantation "First-Line'' Treatment for Severe Clostridium difficile Infection? [J].
Brandt, Lawrence J. ;
Borody, Thomas Julius ;
Campbell, Jordana .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2011, 45 (08) :655-657